NLS Pharmaceutics & Kadimastem Merger Gets Nasdaq Nod
Ticker: NCEL · Form: 6-K · Filed: Oct 23, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: merger, acquisition, regulatory-approval, nasdaq
TL;DR
NLS & Kadimastem merger approved by Nasdaq, closing Oct 30!
AI Summary
NLS Pharmaceutics Ltd. announced on October 23, 2025, that they received Nasdaq approval for their merger with Kadimastem. The merger is anticipated to close on October 30, 2025.
Why It Matters
This Nasdaq approval is a critical step towards the completion of the merger, potentially impacting the combined entity's market presence and future development.
Risk Assessment
Risk Level: medium — Merger completion is subject to closing conditions, and regulatory approvals, while received, can sometimes face unforeseen hurdles.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Filer of the report and party to the merger
- Kadimastem (company) — Party to the merger with NLS Pharmaceutics
- Nasdaq (company) — Exchange where approval was received
- October 30, 2025 (date) — Expected closing date of the merger
- October 23, 2025 (date) — Date of the press release announcing Nasdaq approval
FAQ
What is the expected closing date for the merger between NLS Pharmaceutics and Kadimastem?
The merger is expected to close on October 30, 2025.
What significant approval did NLS Pharmaceutics and Kadimastem announce?
They announced the receipt of Nasdaq approval for their merger.
On what date was the press release regarding the Nasdaq approval issued?
The press release was issued on October 23, 2025.
What is the filing number for this 6-K report?
The accession number for this filing is 0001213900-25-101398.
Where is NLS Pharmaceutics Ltd. headquartered?
NLS Pharmaceutics Ltd. is headquartered in Zurich, Switzerland.
Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2025-10-23 06:04:50
Filing Documents
- ea0262070-6k_nlspharma.htm (6-K) — 11KB
- ea026207001ex99-1_nlspharma.htm (EX-99.1) — 20KB
- 0001213900-25-101398.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 23, 2025 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 3